# CASTLE BIOSCIENCES, INC. (CSTL) · Edgar & Edgarette company card

> Castle Biosciences (CSTL) grew revenue 3.7% in FY2025 to $344 million, operating margin -12.4%, in line with the -12.4% median for medical laboratories, equity 81.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1447362 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CSTL) · [JSON](https://www.pops4.com/boards/company/CSTL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $344M |
| Revenue growth, 1 year | 3.7% |
| Revenue growth per year | 38.3% |
| Operating margin | -12.4% (prior year 2.6%) |
| Net margin | -7.0% |
| Operating cash flow | $64M |
| Capital spending | $36M |
| Free cash flow | $28M |
| Cash | $117M |
| Long-term debt | $10M |
| Total assets | $579M |
| Total equity | $471M |
| Equity ÷ assets | 81.4% |
| Return on equity | -5.1% |
| Dividend per share | $0 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: 6.15 (safe zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating loss: a margin of -12.4% in FY2025; revenue is hard to predict: its 80% range is ±25%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $344.2M (FY2025), total debt $10.1M. Experience: revenue up 3.7% on the year, up 38.3% a year over 4 years; operating margin -12.4%, down from 2.6%. Soundness: equity 81.4% of assets, return on equity -5.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $313.4M and $523.4M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $275.3M to $599.0M. A statistical range, not company guidance. Against peers (17 filers, $50M+ revenue, services-medical laboratories): operating margin -12.4% against a -12.4% median; growth 3.7% against 13.8%.

Range logged 2026-10-31, receipt 8593c19c04073b2e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-07-30 · [filing](https://www.sec.gov/Archives/edgar/data/1447362/000162828026051052/0001628280-26-051052-index.htm)
- 8-K · filed 2026-07-30 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1447362/000162828026051045/0001628280-26-051045-index.htm)
- 8-K · filed 2026-05-29 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1447362/000162828026039189/0001628280-26-039189-index.htm)
- 10-Q · filed 2026-05-06 · [filing](https://www.sec.gov/Archives/edgar/data/1447362/000162828026031263/0001628280-26-031263-index.htm)
- 8-K · filed 2026-05-06 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1447362/000162828026031255/0001628280-26-031255-index.htm)
- DEF 14A · filed 2026-04-08 · [filing](https://www.sec.gov/Archives/edgar/data/1447362/000162828026024166/0001628280-26-024166-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001447362.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1447362

## Cite

POPS4, Edgar & Edgarette: CASTLE BIOSCIENCES, INC. (CSTL) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CSTL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.